For Healthcare Professionals

Safety and Efficacy of Low Dose MM-120 for ADHD Proof of Concept Trial

clipboard-pencil

About the study

This study measures the safety and efficacy of repeated low dose MM-120 as treatment for ADHD in adults: a multi-center, randomized, double-blind, placebo-controlled
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:


  1. Male and female outpatients ≥ 18 and ≤ 65 years of age at Screening
  2. Patients with the diagnosis of Diagnostic and Statistical Manual of Mental Disorders-5 (DSM-5) ADHD, as determined by clinical evaluation and confirmed by structured interview (MINI).
  3. Adequate organ function.
  4. Able to understand the study procedures and understand risks associated with the study, and sign written informed consent to participate in the study.
  5. Must be willing to refrain from more than 6 standard alcoholic drinks a week, more than 10 cigarettes a day, and more than 2 cups of coffee a day throughout the study treatment period (6 weeks) and until the last study visit is complete.

EXCLUSION CRITERIA

Exclusion Criteria:


  1. Past or present diagnosis of a primary psychotic disorder or first degree relative with a psychotic disorder.
  2. Past or present bipolar disorder (DSM-5).
  3. Any lifetime history of suicide attempt.
  4. Once Informed Consent form is signed, not willing or able to stop any prescription or non-prescription ADHD medications.
  5. Use of investigational medication/treatment in the past 30 days.
  6. Patients with a positive urine drug screen with the exception of THC or its metabolites.
  7. Pregnant or nursing females.

pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.

Study’s details


Contition

ADHD,Attention Deficit Disorder

Age (in years)

18 - 65

Phase

Phase 2

Participants needed

53

Est. Completion Date

Dec 8, 2023

Treatment type

Interventional


Sponsor

Mind Medicine, Inc.

ClinicalTrials.gov identifier

NCT05200936

Study number

MMED007

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.